VP5-2022: Updated Progression-Free Survival (PFS) and Depth of Response in IKEMA, a Randomized Phase III Trial of Isatuximab, Carfilzomib and Dexamethasone (Isa-Kd) Vs Kd in Relapsed Multiple Myeloma (MM)
ANNALS OF ONCOLOGY（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要